Cellectar Biosciences, Inc.

CLRB

$11M

Micro Cap

NASDAQBiotechnology🇺🇸North America11 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 22, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Paclitaxel	Phase 3	Non Small Cell Lung Cancer	-
NOV-205	Phase 2	Hepatitis C	-
NOV-002	Phase 2	Ovarian Cancer	-
Iopofosine I 131 single dose	Phase 2	Waldenstrom Macroglobulinemia	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

Dec 22, 2025Iopofosine I 131 single dose

Primary completion for Iopofosine I 131 single dose trial (NCT02952508) in Waldenstrom Macroglobulinemia

Regulatory Approvals

CLRB News